According to Zhitong Finance App, Tonghua Jinma (000766.SZ) announced that on August 6, 2026, the company's wholly-owned subsidiary Guilin Jinma Innovation Investment Co., Ltd. (“Guilin Jinma”) and Eight Plus One Pharmaceutical Co., Ltd. (“Eight Plus One”) jointly signed a “M&A Intent Agreement”. The company intended to acquire the controlling interest of 8 Plus 1 through its wholly-owned subsidiary Guilin Jinma.

According to reports, Eight Plus One is an innovative pharmaceutical company that mainly develops innovative drugs. Its registered place of registration is located in the Guilin Economic and Technological Development Zone. It has obtained 23 drug research and development patents, and has clinical approvals for 2 new Class 1 chemical drugs and 1 new Class 1 type of traditional Chinese medicine. The signing of this agreement of intent is an important step for the company to deepen its layout and accelerate strategic transformation in the field of neurological diseases. It helps the company to rely on the original innovative drug R&D platform and product pipeline of the target company, further enrich the layout of innovative products in the neurological field, enhance the company's comprehensive competitiveness and long-term value in the field of pharmaceutical innovation, and promote the complete transformation and implementation of the company into a comprehensive pharmaceutical enterprise led by R&D and innovation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.